SynthesisPloS one2017
Oral potassium supplementation for management of essential hypertension: A meta-analysis of randomized controlled trials.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Pooled it
- Pooled it
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019Guideline
- Effect of salt substitution on community-wide blood pressure and hypertension incidence.Nature medicine · 2020Trial
- The kidney distal tubule potassium switch, modern diet and hypertension.Nature reviews. Nephrology · 2026Review
- Changes in blood pressure following the relocation of individuals to well-insulated and well-ventilated apartments building.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG).Journal of human hypertension · 2026Article
- The Japanese Society of Hypertension Guidelines for blood pressure control using digital technologies.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Brazilian Guidelines of Hypertension - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Can Dietary Supplements Support Muscle Function and Physical Activity? A Narrative Review.Nutrients · 2025Review
- Biochemical Profiles in Hypertension: Ferritin, Antioxidant Enzymes, and Mineral Levels in Blood Serum.Cureus · 2025Article
- Managing Hypertension in Chronic Kidney Disease: The Role of Diet and Guideline Recommendations.Journal of clinical medicine · 2025Review
- The impact of dietary supplements on blood pressure in older adults: A network meta-analysis of randomized controlled trials.Heliyon · 2024Article
- Urinary Na/K ratio is a predictor of developing chronic kidney disease in the general population.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Salty Subjects: Unpacking Racial Differences in Salt-Sensitive Hypertension.Current hypertension reports · 2024Review
- Review
- Magnesium in hypertension: mechanisms and clinical implications.Frontiers in physiology · 2024Review
- Association of serum potassium level with dietary potassium intake in Chinese older adults: a multicentre, cross-sectional survey.BMJ open · 2023Article
- Overview of research progress on the association of dietary potassium intake with serum potassium and survival in hemodialysis patients, does dietary potassium restriction really benefit hemodialysis patients?Frontiers in endocrinology · 2023Review
- A Mobile Health-Based Disease Management Program Improves Blood Pressure in People With Multiple Lifestyle-Related Diseases at Risk of Developing Vascular Disease - A Retrospective Observational Study.Circulation reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceIncreased dietary potassium intake is thought to be associated with low blood pressure (BP). Whether potassium supplementation may be used as an antihypertensive agent is a question that should be answered.
objectiveTo assess the effect of oral potassium supplementation on blood pressure in patients with primary hypertension. SEARCH
methodsWe searched Medline, Web of Science, Scopus, Cochrane Central Register of Controlled Trials until October 2016. We also screened reference lists of articles and previous reviews. We applied no language restrictions. SELECTION CRITERIA: We included randomized placebo-controlled clinical trials addressing the effect of potassium supplementation on primary hypertension for a minimum of 4 weeks. DATA COLLECTION AND ANALYSIS: We extracted data on systolic and diastolic BP (SBP and DBP) at the final follow-up. We explored the heterogeneity across studies using Cochran's test and I2 statistic and assessed the probability of publication bias using Begg's and Egger's tests. We reported the mean difference (MD) of SBP and DBP in a random-effects model.
resultsWe found a total of 9059 articles and included 23 trials with 1213 participants. Compared to placebo, potassium supplementation resulted in modest but significant reductions in both SBP (MD -4.25 mmHg; 95% CI: -5.96 to -2.53; I2 = 41%) and DBP (MD -2.53 mmHg; 95% CI: -4.05 to -1.02; I2 = 65%). According to the change-score analysis, based on 8 out of 23 trials, compared to baseline, the mean changes in SBP (MD -8.89 mmHg; 95% CI: -13.67 to -4.11) and DBP (MD -6.42 mmHg; 95% CI: -10.99 to -1.84) was significantly higher in the intervention group than the control group.
conclusionsOur findings indicated that potassium supplementation is a safe medication with no important adverse effects that has a modest but significant impact BP and may be recommended as an adjuvant antihypertensive agent for patients with essential hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.